Investigational Scleroderma Drug Takes Novel Approach To Treating Inflammation. A new proposed treatment for scleroderma, Resunab, will soon be in Phase 2 clinical trials. Scleroderma News, 03/16/2015. (Also see Scleroderma Clinical Trials: Resunab)
New Study Summarizes Scientific Findings Concerning Scleroderma Renal Crisis (SRC). SRC is still affecting a meaningful population of patients with systemic sclerosis, so a vigilant diagnosis and therapy is needed to prevent adverse outcomes and enhance survival. Seminars in Arthritis and Rheumatism, 02/27/2015. (Also see Scleroderma Renal Crisis)
Researchers Report Audiovestibular Dysfunction in Systemic Sclerosis Patients. There is an association between systemic sclerosis and inner ear function resulting in audiovestibular abnormalities. The Egyptian Rheumatologist, 02/26/2015. (Also see Autoimmune Ear Diseases)
A preliminary study of acoustic radiation force impulse (ARFI) quantification for the assessment of skin in diffuse cutaneous systemic sclerosis (dSSc). ARFI quantification is feasible and reliable for assessing the skin involvement in dcSSc and may be a valuable adjunct to skin evaluation in patients with SSc. PubMed, J Rheumatol, 2015 Mar;42(3):449-55. (Also see Skin Fibrosis)
Decreased numbers of endothelial progenitor cells (EPCs) in patients in the early stages of systemic sclerosis (SSc). Decreased EPCs in SSc patients might be an important therapeutic target for the prevention of vascular complications. PubMed, Microvasc Res, 2015 Jan 13;98C:82-87. (Also see Vascular Involvement in Systemic Scleroderma)
A reactive oxygen species(ROS)-mediated loop maintains the increased expression of NOX2 and NOX4 in skin fibroblasts from patients with systemic sclerosis (SSc). NOX2 and NOX4 generate ROS in SSc fibroblasts and play a critical role in cell activation and DNA damage. PubMed, Arthritis Rheumatol, 02/23/2015. (Also see Causes of Scleroderma: Fibroblasts)
Early systemic sclerosis-opportunities for treatment. The early diagnosis of SSc, before the development of fibrosis in internal organs, will allow the introduction of immunosuppressive medications in these patients in a controlled setting. PubMed, Clin Rheumatol, 02/26/2015. (Also see Common Medical Tests for Scleroderma)
Interstitial Lung Disease in Scleroderma. The diagnosis of interstitial lung disease hinges on careful clinical evaluation and pulmonary function tests and high-resolution computed tomography. Rheumatic Disease Clinics of North America, 03/05/2015. (Also see Pulmonary Fibrosis Diagnosis)
United Way of Central New Mexico
United Way of Snohomish County
See ISN News for recent donors, including Juliet Youkhana; and donations in loving memory of Jim Miller and Arlene Marie Petulla.
Click Here to Donate or Shop
or click on the floating green DONATE sclero.org button.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: